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Summary
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by 
vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that 
expresses the spike protein of SARS-CoV-2.
Methods We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee 
adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal 
conjugate vaccine (MenACWY) as control. Healthy adults aged 18–55 years with no history of laboratory confirmed 
SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose 
of 5 × 10¹⁰ viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites 
allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, 
unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 
28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised 
total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 
neutralisation assays (a 50% plaque reduction neutralisation assay [PRNT50]; a microneutralisation assay [MNA50, MNA80, 
and MNA90]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo 
interferon-γ enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of 
symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. 
Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after 
vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune 
responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.
Findings Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either 
ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 
nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and 
many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, 
and malaise (all p<0·05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 
group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood 
mononuclear cells, IQR 493–1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 
96–317; n=127), and were boosted following a second dose (639 EU, 360–792; n=10). Neutralising antibody responses 
against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA80 and in 
35 (100%) participants when measured in PRNT50. After a booster dose, all participants had neutralising activity (nine of 
nine in MNA80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly 
with antibody levels measured by ELISA (R²=0·67 by Marburg VN; p<0·001).
Interpretation ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody 
responses. These results, together with the induction of both humoral and cellular immune responses, support large-
scale evaluation of this candidate vaccine in an ongoing phase 3 programme.
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Introduction
Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) emerged as a zoonotic virus late in 2019 
and is the causative agent of COVID-19. Exposure to 
SARS-CoV-2 can result in a range of clinical outcomes, 
varying from asymptomatic infection to severe acute 
respiratory distress and death. SARS-CoV-2 has spread 
globally and was declared a pandemic on March 11, 2020, 
by WHO. As of July 19, 2020, more than 14 million 
people globally have been infected with more than 
597 000 deaths.1 The pandemic has placed substantial 
pressures on health systems delivering care for patients 
with COVID-19 and caused disruption of non-COVID-19 
health-care provision, in addition to negative effects on 
the global economy. Further health consequences are 
anticipated.
No vaccines have been approved for prevention of 
COVID-19. There are currently more than 137 candidates 
undergoing preclinical development and 23 in early 
clinical development, according to WHO.2 An ideal 
vaccine against SARS-CoV-2 would be effective after 
one or two vaccinations; would protect target populations 
such as older adults and those with comorbidities, 
including immunocompromised individuals; would 
confer protection for a minimum of 6 months; and 
would reduce onward transmission of the virus to 
contacts. Replication-deficient viral vectored vaccines 
have been used in immunocompromised individuals 
with no safety concerns3–5 and ChAdOx1 vaccines are 
immunogenic in older adults6 and can be manufactured 
at large scale, making this platform technology a 
promising candidate to develop a vaccine for the 
prevention of COVID-19. Adenoviral vectors have previ-
ously been combined with DNA and poxviral vectors to 
attempt to improve immunogenicity, with adenovirus or 
modified vaccinia virus Ankara prime-boost regimens 
showing enhancement of both cellular and humoral 
immunity. Use of homologous adenoviral regimens has 
largely been avoided because of presumed induction of 
antivector immunity, inhibiting the potency of a second 
dose.
Coronaviruses are enveloped, positive sense single-
stranded RNA viruses with a glycoprotein spike on the 
surface, which mediates receptor binding and cell entry 
during infection. The roles of the spike protein in receptor 
binding and membrane fusion make it an attractive 
vaccine antigen. We have previously shown that a single 
dose of ChAdOx1 MERS, a chimpanzee adenovirus-
vectored vaccine that encodes the spike protein of Middle 
East respiratory syndrome coronavirus (MERS-CoV), 
protected non-human primates against MERS-CoV-
induced disease,7 and data from a phase 1 clinical trial 
showed that ChAdOx1 MERS was safe and well tolerated 
at all three doses tested (5 × 10⁹ viral particles, 2·5 × 10¹⁰ 
viral particles, and 5 × 10¹⁰ viral particles).8 In addition, the 
highest dose elicited both humoral and cellular responses 
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Research in context
Evidence before this study
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
was identified as the causative agent of COVID-19 in 
January, 2020. There are currently no licensed vaccines to 
prevent COVID-19. ChAdOx1 nCoV-19 has previously been 
reported to be immunogenic and protective against 
pneumonia in a rhesus macaque challenge model. We searched 
PubMed for research articles published between database 
inception and July 6, 2020, using the terms “SARS-CoV-2”, 
“vaccine”, “clinical trial”, and “phase”. No language restrictions 
were applied. We identified one published clinical trial, 
describing a trial done in China of an adenovirus-5-vectored 
vaccine against SARS-CoV-2, using a single dose at 
three different dose levels. The vaccine was tolerated, 
with reactogenicity increased at the highest dose. Antibodies, 
neutralising antibodies in a proportion of vaccinees, and cellular 
responses were induced. A further clinical trial, which was done 
in the USA, has been reported on medRxiv. The vaccine was a 
lipid nanoparticle-formulated, nucleoside-modified, mRNA 
vaccine that encodes trimerised SARS-CoV-2 spike glycoprotein 
receptor binding domain administered at one or two doses of 
three dose levels. The vaccine was tolerated, with reactogenicity 
increased at the highest dose. Antibodies and neutralising 
antibodies were induced in a dose-dependent manner and 
increased after a second dose.
 Added value of this study
We report the results of the first clinical study of ChAdOx1 
nCoV-19 (AZD1222). The vaccine was safe and tolerated, 
with reduced reactogenicity when paracetamol was used 
prophylactically for the first 24 h after vaccination. 
Reactogenicity was reduced after a second dose. Humoral 
responses to SARS-CoV-2 spike protein peaked by day 28 post 
prime and cellular responses were induced in all participants by 
day 14. Neutralising antibodies were induced in all participants 
after a second vaccine dose. After two doses, potent cellular 
and humoral immunogenicity was present in all participants 
studied.
 Implications of all the available evidence
A vaccine against SARS-CoV-2 could be used to prevent 
infection, disease, and death in the global population, 
with high-risk populations such as hospital workers and older 
adults (eg, ≥65 years of age) prioritised to receive vaccination. 
The immune correlates of protection against SARS-CoV-2 
have not yet been determined. Immunisation with 
ChAdOx1 nCoV-19 results in rapid induction of both humoral 
and cellular immune responses against SARS-CoV-2, with 
increased responses after a second dose. Further clinical 
studies, including in older adults, should be done with this 
vaccine.
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against MERS-CoV in all vaccinees within 1 month of 
vaccination.
The ChAdOx1 nCoV-19 vaccine (AZD1222) consists 
of the replication-deficient simian adenovirus vector 
ChAdOx1, containing the full-length structural surface 
glycoprotein (spike protein) of SARS-CoV-2, with a tissue 
plasminogen activator leader sequence. ChAdOx1 nCoV-19 
expresses a codon-optimised coding sequence for the spike 
protein (GenBank accession number MN908947).
In rhesus macaques, a single vaccination with ChAdOx1 
nCoV-19 induced humoral and cellular immune responses. 
Protection against lower respiratory tract infection was 
observed in vaccinated non-human primates after high-
dose SARS-CoV-2 challenge.9
We did a phase 1/2 single-blind, randomised controlled 
trial of ChAdOx1 nCoV-19 compared with a licensed 
meningococcal group A, C, W-135, and Y conjugate 
vaccine (MenACWY; Nimenrix, Pfizer, UK), as control 
vaccine, in healthy adults in the UK. In this preliminary 
report, we describe the immunogenicity, reactogenicity, 
and safety of vaccination with 5 × 10¹⁰ viral particles of 
ChAdOx1 nCoV-19 in single-dose and two-dose regimens.
Methods
Study design and participants
This phase 1/2, participant-blinded, multicentre, random-
ised controlled trial is being done at five centres in the UK 
(Centre for Clinical Vaccinology and Tropical Medicine, 
University of Oxford; NIHR Southampton Clinical 
Research Facility, University Hospital South ampton NHS 
Foundation Trust, Southampton; Clinical Research Facility, 
Imperial College London; St Georges University of London 
and University Hospital NHS Foundation Trust; and 
University Hospitals Bristol and Weston NHS Foundation 
Trust). Healthy adult partici pants aged 18–55 years were 
recruited through local advertisements. All participants 
underwent a screening visit where a full medical history 
and examination was taken in addition to blood and urine 
tests (HIV; hepatitis B and C serology; full blood count; 
kidney and liver function tests; and urinary screen for 
blood, protein, and glucose and a pregnancy test done in 
women of childbearing potential). Volunteers with a 
history of laboratory confirmed SARS-CoV-2 infection; 
those at higher risk for SARS-CoV-2 exposure pre-
enrolment (ie, front-line health-care workers working in 
emergency departments, intensive care units, and 
COVID-19 wards, and close contacts of confirmed 
COVID-19 cases; see appendix p 82 for further details); and 
those with a new onset of fever, cough, shortness of breath, 
and anosmia or ageusia since Feb 1, 2020, were excluded 
from the study. An amendment to the study protocol 
(amendment date April 21, 2020) allowed for recruitment 
of health-care workers with a negative SARS-CoV-2 
serology at screening, once an antibody test became 
available. As it was not possible to screen for negative 
SARS-CoV-2 serology in all partici pants, some enrolled 
participants had high-level anti-spike antibodies at baseline 
and their data are included in all analyses. Full details of 
the eligibility criteria are described in the trial protocol 
provided in the appendix (pp 80–82).
Written informed consent was obtained from all 
participants, and the trial is being done in accor dance 
with the principles of the Declaration of Helsinki and 
Good Clinical Practice. This study was approved in 
the UK by the Medicines and Healthcare products 
Regulatory Agency (reference 21584/0424/001-0001) and 
the South Central Berkshire Research Ethics Committee 
(reference 20/SC/0145). Vaccine use was authorised by 
Genetically Modified Organisms Safety Committees at 
each participating site.
Randomisation and masking
Participants were randomly assigned (1:1) to receive 
either the ChAdOx1 nCoV-19 vaccine or the MenACWY 
vaccine. MenACWY was used as a comparator vaccine to 
maintain blinding of participants who experienced local 
or systemic reactions, since these reactions are a known 
association with viral vector vaccinations. Use of saline 
as a placebo would risk unblinding participants as those 
who had notable reactions would know they were in the 
ChAdOx1 nCoV-19 vaccine group.
Randomisation lists, using block randomisation 
stratified by study group and study site, were generated 
by the study statistician (MV). Block sizes of two and four 
were chosen to align with the study group sizes and the 
sequence of enrolment, and varied across study groups. 
Computer randomisation was done with full allocation 
concealment within the secure web platform used for the 
study electronic case report form (REDCap version 9.5.22; 
Vanderbilt University, Nashville, TN, USA). The trial 
staff administering the vaccine prepared vaccines out of 
sight of the participants and syringes were covered with 
an opaque material until ready for administration to 
ensure blinding of participants. Clinical investigators 
and the laboratory team remained blinded to group 
allocation.
Procedures
The recombinant adenovirus for ChAdOx1 nCoV-19 was 
produced as previously described.10 The vaccine was 
manufactured according to current Good Manufacturing 
Practice by the Clinical BioManufacturing Facility 
(University of Oxford, Oxford, UK) as previously 
described,11 with only minor modifications, as described 
in the Investigational Medicinal Product Dossier and 
approved by the regulatory agency in the UK. ChAdOx1 
nCoV-19 was administered at a dose of 5 × 10¹⁰ viral 
particles. The MenACWY vaccine was provided by the 
UK Department of Health and Social Care and admin-
istered as per summary of product characteristics at the 
standard dose of 0·5 mL. Vaccines were administered as 
a single intramuscular injection into the deltoid. 
Participants were recruited and followed up accor ding 
to groups. Participants were recruited first for groups 1 
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and 3, then group 2, and then group 4. Group 1 (the 
phase 1 component of the study) consisted of participants 
who had intensive early follow-up visits for safety and 
immunogenicity purposes at days 3, 7, 14, 28, and 56 after 
vaccination. Group 2 consisted of participants who had 
higher blood volumes drawn for humoral and cellular 
immunogenicity assessment than group 4, which 
consisted of participants who had a serum sample drawn 
for humoral immunology assessments only. Group 3 
consisted of ten participants who were enrolled in a non-
randomised prime-boost group and received a booster 
ChAdOx1 nCoV-19 administered 28 days after the first 
dose. These participants were not blinded and had 
extensive follow-up for safety and immunogenicity 
purposes, as per group 1, after each dose. A staggered-
enrolment approach was used for the first two, six, and 
90 participants recruited in groups 1 and 3 (appendix 
p 89) and interim safety reviews with the independent 
Data and Safety Monitoring Board were done before 
proceeding with vaccinations in larger numbers of 
volunteers. Volunteers were considered enrolled into the 
trial at the point of vaccination.
Participants in all groups had blood samples drawn 
and clinical assessments for safety as well as immu-
nology at days 0 and 28, and will also be followed up at 
days 184 and 364. A later amendment to the protocol 
(amendment date June 22, 2020) provided for additional 
testing of booster vaccinations in a subset of participants, 
the results of which are not yet available and are not 
included in this Article.
In two of the five trial sites (Oxford and Southampton), 
a protocol amendment (amendment date May 6, 2020) 
was implemented to allow prophylactic paracetamol to 
be administered before vaccination and participants were 
advised to continue with 1 g of paracetamol every 6 h 
for 24 h to reduce vaccine-associated reactions. All 
partic ipants enrolled after the protocol amendment at 
these two sites were given prophylactic paracetamol and 
randomised equally to the vaccine or control arms of the 
study.
Participants were observed in the clinic for 30–60 min 
after the vaccination procedure and were asked to record 
any adverse events using electronic diaries during the 
28-day follow-up period. Expected and protocol-defined 
local site reactions (injection site pain, tenderness, 
warmth, redness, swelling, induration, and itch) and 
systemic symptoms (malaise, muscle ache, joint pain, 
fatigue, nausea, headache, chills, feverishness [ie, a self-
reported feeling of having a fever], and objective fever 
defined as an oral temperature of 38°C or higher) were 
recorded for 7 days. All other events were recorded for 
28 days and serious adverse events are recorded 
throughout the follow-up period.
Severity of adverse events are graded with the following 
criteria: mild (transient or mild discomfort for <48 h, no 
interference with activity, and no medical intervention or 
therapy required), moderate (mild to moderate limitation 
in activity [some assistance might be needed] and no or 
minimal medical intervention or therapy required), 
severe (marked limitation in activity [some assistance 
usually required] and medical inter vention or therapy 
required), and potentially life-threatening (requires 
assessment in emergency department or hospitali-
sation). Unsolicited adverse events are reviewed for 
causality by two clinicians blinded to group allocation, 
and events considered to be possibly, probably, or 
definitely related to the study vaccines were reported. 
Laboratory adverse events were graded by use of site-
specific toxicity tables, which were adapted from 
the US Food and Drug Administration toxicity grading 
scale.
Cellular responses were assessed using an ex-vivo 
interferon-γ enzyme-linked immunospot (ELISpot) 
assay to enumerate antigen-specific T cells. Humoral 
responses at baseline and following vaccination were 
assessed using a standardised total IgG ELISA against 
trimeric SARS CoV-2 spike protein, a muliplexed 
immunoassay (Meso Scale Discovery multiplexed 
immu noassay [MIA] against spike and receptor binding 
domain), three live SARS-CoV-2 neutralisation assays 
(Public Health England [PHE] plaque reduction 
neutralisation test [PRNT IC50], PHE micro neutralisation 
assay [MNA IC50, IC80, IC90], and Marburg virus 
neutralisation [VN IC100]), and a pseudovirus neutral-
isation assay (PseudoNA IC50). PHE PRNT is a live 
neutralisation assay and was done at PHE (Porton 
Down, UK). PHE MNA is a rapid microneutralisation 
assay, which was conducted in the same laboratory. The 
third assay, Marburg VN, was conducted at Marburg 
University (Marburg, Germany). Full details on the 
assays are provided in the appendix (pp 31–34). Owing 
to the labour-intensive nature of some of these assays, 
we prioritised analysis of samples from the ChAdOx1 
nCoV-19 group, randomly selecting more samples from 
ChAdOx1 nCoV-19 participants than control samples to 
be sent for analysis.
Convalescent plasma samples from adults (≥18 years) 
with PCR-positive SARS-CoV-2 infection were obtained 
from symptomatic patients admitted to hospital or from 
surveillance on health-care workers who did not have 
symptomatic infection. These samples were tested using 
standardised ELISA, MIA, PseudoNA, and Marburg VN. 
Different samples were analysed across the assays, 
dependent on sample availability, laboratory capacity, 
and assay-specific requirements. Where multiple 
longitudinal samples were available for the same 
participant, only one timepoint is included in the 
analyses in this Article and the earliest timepoint (at 
least 20 days after initial symptoms) was selected.
Outcomes
The co-primary outcomes are to assess efficacy 
as measured by cases of symptomatic virologically 
confirmed COVID-19 and safety of the vaccine as 
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measured by the occurrence of serious adverse events. 
Secondary out comes include safety, reactogenicity, 
and immunogenicity profiles of ChAdOx1 nCoV-19, and 
efficacy against hospital-attended COVID-19, death, and 
seroconversion against non-spike proteins (appendix 
pp 72–73). Prelim inary results for secondary endpoints 
are reported here: occurrence of local and systemic 
reactogenicity signs and symptoms for 7 days after 
vaccination; occurrence of unsolicited adverse events 
for 28 days after vaccination; change from day 0 
(baseline) to day 28 for safety laboratory measures; and 
cellular and humoral immunogenicity of ChAdOx1 
nCoV-19. Neutralising antibodies and laboratory adverse 
events were tested on participants in groups 1 and 3 
only. Unsolicited adverse events are reported for group 1 
only.
The convalescent sample collection of PCR-positive 
hospitalised patients with COVID-19 or asymptomatic 
health-care workers was done to characterise the 
immunological properties of COVID-19 and not for the 
purposes of the clinical trial (Gastrointestinal Illness in 
Oxford: COVID substudy [Sheffield Research Ethics 
Committee reference: 16/YH/0247], ISARIC/WHO 
Clinical Characterisation Protocol for Severe Emerging 
Infections [Oxford Research Ethics Committee C 
reference 13/SC/0149], and Sepsis Immunomics project 
[Oxford Research Ethics Committee C, reference 
19/SC/0296]).
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Statistical analysis
Safety endpoints are described as frequencies (%) with 
95% binomial exact CIs. Medians and IQRs are pres-
ented for immunological endpoints and analyses are 
considered descriptive only, as the full set of samples 
have not yet been analysed on all platforms and 
therefore results reported here are preliminary. Partic-
ipants were analysed according to the group to which 
they were randomised. To assess the effect of 
prophylactic paracetamol use, the occurence of adverse 
reactions in the first 2 days after vaccination was 
analysed as a binary variable using adjusted logistic 
regression with results presented as adjusted odds 
ratios. The model adjusted for age, sex, occupation 
(health-care worker or not), smoking, alcohol consump-
tion, and body-mass index. To assess the relationship 
between responses on different assays, linear regression 
was used to analyse log-transformed post-baseline 
values. Statis tical analyses were done using SAS 
version 9.4 and R version 3.6.1 or later.
The sample size for the study was determined by the 
number of doses of vaccine that were available for 
use after the initial clinical manufacturing process. 
Sample sizes for efficacy are based on the number of 
Figure 1: Solicited local (A) and systemic (B) adverse reactions in first 7 days after vaccination as recorded in participant symptom electronic diaries
Day 0 is the day of vaccination. P=60-min post-vaccination observation period in the clinic. MenACWY=meningococcal group A, C, W-135, and Y conjugate vaccine. *Mild: 38·0°C to <38·5°C; moderate: 
38·5°C to <39·0°C; severe: ≥39·0°C. †Self-reported feeling of feverishness.
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primary outcome events that accrue and are presented in 
the protocol (appendix pp 116–117). Efficacy ana lyses have 
not yet been done and are not included in this Article.
An independent data and safety monitoring board 
provided safety oversight (appendix p 46). This study is 
registered with ClinicalTrials.gov, NCT04324606, and 
with ISRCTN, 15281137.
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between April 23 and May 21, 2020, 1077 participants were 
enrolled into the study and assigned to vaccination with 
either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534; 
appendix p 3); ten of these participants were enrolled in 
group 3, the prime-boost group, and thus were not 
randomly assigned. 88 participants were included in 
Figure 2: Solicited local (A) and systemic (B) adverse reactions in first 7 days after priming and booster doses of ChAdOx1 nCoV-19 in the non-randomised subset of ten participants
Day 0 is the day of vaccination. P=60-min post-vaccination observation period in the clinic. *Mild: 38·0°C to <38·5°C; moderate: 38·5°C to <39·0°C; severe: ≥39·0°C. †Self-reported feeling 
of feverishness.
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group 1, 412 in group 2, and 567 in group 4 (appendix p 3). 
All randomised participants were vaccinated; one par-
ticipant in the MenACWY group received the ChAdOx1 
nCoV-19 vaccine (appendix p 3).
The median age of participants was 35 years 
(IQR 28–44 years), 536 (49·8%) participants were female 
and 541 (50·2%) were male, and the majority of par-
ticipants (979 [90·9%]) were white (appendix p 4). 
Baseline characteristics seemed similar between random-
ised groups (appendix p 4).
56 participants in the ChAdOx1 nCoV-19 group and 
57 in the MenACWY group received prophylactic 
paracetamol. In those who did not receive prophylactic 
paracetamol, 328 (67%) of 487 participants in the 
ChAdOx1 nCoV-19 group and 180 (38%) of 477 participants 
in the MenACWY group reported pain after vaccination, 
which was mostly mild to moderate in intensity 
(appendix pp 5–7). With prophylactic paracetamol, pain 
was reported by fewer participants: 28 (50%) in the 
ChAdOx1 nCoV-19 group and 18 (32%) in the MenACWY 
group. Tenderness of mostly mild intensity was reported 
in the ChAdOx1 nCoV-19 group by 403 (83%) participants 
without paracetamol and 43 (77%) with paracetamol, 
and in the MenACWY group by 276 (58%) participants 
without paracetamol and 26 (46%) with paracetamol 
(figure 1; appendix pp 5–7).
Fatigue and headache were the most commonly 
reported systemic reactions. Fatigue was reported in 
the ChAdOx1 nCoV-19 group by 340 (70%) participants 
without paracetamol and 40 (71%) with paracetamol 
and in the MenACWY group by 227 (48%) participants 
without paracetamol and 26 (46%) with paracetamol, 
whereas headaches were reported in the ChAdOx1 
nCoV-19 group by 331 (68%) participants without 
paracetamol and 34 (61%) with paracetamol and in 
the MenACWY group by 195 (41%) participants 
without paracetamol and 21 (37%) participants with 
paracetamol.
Other systemic adverse reactions were common in the 
ChAdOx1 nCoV-19 group: muscle ache (294 [60%] 
participants without paracetamol and 27 [48%] with 
paracetamol), malaise (296 [61%] and 27 [48%]), chills 
(272 [56%] and 15 [27%]); and feeling feverish (250 [51%] 
and 20 [36%]). In the of ChAdOx1 nCoV-19 group, 
87 (18%) participants without paracetamol and nine (16%) 
participants with paracetamol reported a temperature of 
at least 38°C, and eight (2%) patients without paracetamol 
had a temperature of at least 39°C. In comparison, 
two (<1%) of those receiving MenACWY reported a fever 
of at least 38°C, none of whom were receiving prophylactic 
paracetamol (figure 1; appendix pp 5–7).
The severity and intensity of local and systemic 
reactions was highest on day 1 after vaccination (figure 1).
Adjusted analysis of the effect of prophylactic paracet-
amol on adverse reactions of any severity in the first 2 days 
after vaccination with ChAdOx1 nCoV-19 showed signif-
icant reductions in pain, feeling feverish, chills, muscle 
ache, headache, and malaise (appendix pp 10–11).
All ten participants in the prime-boost group received 
their booster vaccine at day 28; solicited local and systemic 
reactions were measured in these participants for 7 days 
after both the prime and booster doses. The reactogenicity 
Figure 3: SARS-CoV-2 IgG response by standardised ELISA to spike protein in trial participants (A) and in 180 convalescent plasma samples from 172 patients 
with PCR-confirmed COVID-19 and eight asymptomatic health-care workers (B)
Error bars show median (IQR). Participants in the prime boost group received their second dose at day 28. Lower limit of quantification is 1 ELISA unit. Red stars in 
panel B show five samples also tested on the Marburg VN assay (see figure 4). MenACWY=meningococcal group A, C, W-135, and Y conjugate vaccine. 
SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
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profile after the second dose appeared less severe in this 
subset, although the small number of participants in this 
group led to wide CIs (figure 2; appendix pp 8–9).
Unsolicited adverse events in the 28 days following 
vaccination considered to be possibly, probably, or 
definitely related to ChAdOx1 nCoV-19 were predom-
inantly mild and moderate in nature and resolved within 
the follow-up period (appendix pp 12–15). Laboratory 
adverse events considered to be at least possibly related 
to the study intervention were self-limiting and 
predominantly mild or moderate in severity (data not 
shown). Transient haematological changes from base-
line (neutropenia) were observed in 25 (46%) of 
54 participants in the ChAdOx1 nCoV-19 group compared 
with three (7%) of 44 participants in the MenACWY 
group. There was one serious adverse event in the 
MenACWY group consisting of a new diagnosis of 
haemolytic anaemia, occurring 9 days after vaccination. 
The participant was clinically well throughout the study. 
The event was reported as a suspected unexpected 
serious adverse reac tion relating to the MenACWY 
vaccine.
In the ChAdOx1 nCoV-19 group, antibodies against 
SARS-CoV-2 spike protein peaked by day 28 (median 
157 ELISA units [EU], IQR 96–317; n=127) and remained 
elevated to day 56 (119 EU, 70–203; n=43) in participants 
who received only one dose, and increased to a median of 
639 EU (360–792) at day 56 in the ten participants who 
received a booster dose (figure 3).
Figure 4: Live SARS-CoV-2 neutralisation assays (Marburg VN and PHE PRNT50) and microneutralisation assays (PHE MNA)
Panels A and B show live SARS-CoV-2 neutralisation (Marburg VN) in prime (A) and prime boost (B) trial participants (boosted at day 28) and convalescent plasma 
from patients with PCR-confirmed COVID-19 and asymptomatic health-care workers. Panels C, E, and F show the PHE MNA (at IC50, IC80, and IC90, respectively) and 
panel D the PHE PRNT50. The day 42 timepoint was only measured in participants who received a booster dose at day 28. Solid lines connect samples from the same 
participant. Boxes show median (IQR). Dotted lines show upper limits of detection. MenACWY=meningococcal group A, C, W-135, and Y conjugate vaccine. 
PHE=Public Health England. MNA=microneutralisation assay. PRNT=plaque reduction neutralisation test. VN=virus neutralisation. IC=inhibitory concentration. 
SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. *ELISA results for these five convalescent plasma samples are shown in figure 3 as red stars.
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Figure 5: PseudoNA results in trial participants and in convalescent plasma samples from 146 patients with 
PCR-confirmed COVID-19 and 24 asymptomatic health-care workers
Solid lines connect samples from the same participant. Boxes show median (IQR). Results for days 35 and 42 
are samples from participants who received a booster dose at day 28. IC=inhibitory concentration. 
MenACWY=meningococcal group A, C, W-135, and Y conjugate vaccine. 
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Similar increases in serum antibody levels to both the 
spike protein and the receptor binding domain by day 28 
and after a booster dose were observed when measured by 
MIA (appendix p 16). Immunogenicity among those 
who were advised to take paracetamol prophylactically was 
similar to that seen among those who were not advised 
to use it prophylactically (data not shown).
In the PHE PRNT50 assay, which determined the 
extent to which serum can be diluted and still reduce 
SARS-CoV-2 plaque formation by 50%, 35 (100%) of 
35 participants achieved neutralising titres with a median 
titre of 218 (IQR 122–395) at day 28 and similar results 
were obtained with the PHE MNA80 assay, with titres 
inducing 80% virus neutralisation achieved in 32 (91%) of 
35 participants after one dose (median titre 51, 32–103), 
and in nine (100%) of nine participants after the booster 
dose (median titre 136, 115–241; figure 4; appendix 
pp 17–19). In the Marburg VN assay, 23 (62%) of 
37 recipients had neutralising antibodies that induced 
complete inhibition of the cytopathic effect caused by 
SARS-CoV-2 by day 56 after one dose, as did ten (100%) of 
ten participants after a booster dose, with a median titre 
of 29 (24–32; figure 4).
Titres from the PseudoNA assay and the Marburg VN 
assay correlated positively with other live virus neutrali-
sation assay titres and with ELISA (PseudoNA R²=0·53 and 
Marburg VN R²=0·67; both p<0·001; figure 4, 5; appendix 
pp 20–21). We included responses following natural expo-
sure as a point of reference for vaccine response data, and 
found that vaccine-induced responses were in a similar 
range (figure 5). Interferon-γ ELISpot responses against 
SARS-CoV-2 spike peptides peaked at 856 spot-forming 
cells per million peripheral blood mononuclear cells 
(IQR 493–1802; n=43) at day 14, declining to 424 (221–799; 
n=43) by day 56 after vaccination (figure 6).
A small number (four [4%] of 98) participants had 
neutralising antibody titres greater than 8 against 
SARS-CoV-2 spike protein before vaccination (Marburg 
VN) and 11 (4%) of 270 participants had high ELISA titres 
at baseline, representing possible prior asymptomatic 
infection.
Before vaccination, only one (1%) of 98 participants 
who were tested had high titre (>200) neutralising 
antibodies against ChAdOx1. Antibodies were detectable 
at a lower level in a further 18 (1%) participants, and 
in 79 (81%) participants there were no detectable anti-
ChAdOx1 antibodies. We found no rela tionship between 
presence of low-level antibodies to ChAdOx1 on the day 
of vaccination and the ELISA titre to SARS-CoV-2 spike 
protein in those randomly assigned to receive ChAdOx1 
nCoV-19 (appendix p 22).
Discussion
Our preliminary findings show that the candidate 
ChAdOx1 nCoV-19 vaccine given as a single dose was safe 
and tolerated, despite a higher reactogenicity profile than 
the control vaccine, MenACWY. No serious adverse 
reactions to ChAdOx1 nCoV-19 occurred. The majority 
of adverse events reported were mild or moderate in 
severity, and all were self-limiting. The profile of adverse 
events reported here is similar to that for other ChAdOx1-
vectored vaccines and other closely related simian 
adenoviruses, such as ChAdOx2, ChAd3, and ChAd63, 
expressing multiple different antigens8,12–14 at this dose 
level, as well as to some licensed vaccines.15 A dose of 
5 × 10¹⁰ viral particles was chosen on the basis of our 
previous experience with ChAdOx1 MERS, where despite 
increased reactogenicity, a dose–response relationship 
with neutralising antibodies was observed.8 The protocol 
was written when the pandemic was accelerating in 
the UK and a single higher dose was chosen to provide 
the highest chance of rapid induction of neutralising 
antibody. In the context of a pandemic wave where a 
single higher, but more reactogenic, dose might be more 
likely to rapidly induce protective immunity, the use of 
prophylactic paracetamol appears to increase tolerability 
and would reduce confusion with COVID-19 symptoms 
that might be caused by short-lived vaccine-related symp-
toms without compromising immunogenicity.
We show that a single dose of ChAdOx1 nCoV-19 elicits 
an increase in spike-specific antibodies by day 28 and 
neutralising antibody in all participants after a booster 
dose. High levels of neutralising antibody at baseline 
seen in a small number of participants probably indicates 
prior asymptomatic infection, as potential participants 
with recent COVID-19-like symptoms or with a history of 
positive PCR test for SARS-CoV-2 were excluded from 
the study. Individuals with high titres on the day of 
vaccination who received ChAdOx1 nCoV-19 were boosted 
by vaccination.
Neutralising antibodies targeting different epitopes of 
the spike glycoprotein have been associated with protec-
tion from COVID-19 in early preclinical rhesus macaque 
studies.16 Although a correlate of protection has not been 
Figure 6: Interferon-γ ELISpot response to peptides spanning the SARS-CoV-2 spike vaccine insert
Error bars show median (IQR). The lower limit of detection, indicated with the dotted line, is 48 spot-forming cells 
per million PBMCs. PBMC=peripheral blood mononuclear cell. SARS-CoV-2=severe acute respiratory syndrome 
coronavirus 2. ELISpot=enzyme linked immunospot. MenACWY=meningococcal group A, C, W-135, and Y conjugate 
vaccine. 
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defined for COVID-19, high levels of neutralising 
antibodies have been shown in convalescent individuals, 
with a wide range, as confirmed in our study.17,18
Antibodies capable of neutralising live SARS-CoV-2 were 
induced by day 28 with titres of 51 (PHE MNA80) and 
218 (PHE PRNT50), and with titres of 29 (Marburg VN) or 
136 (PHE MNA80) after a booster dose, as measured using 
different assays. In a non-human primate study where 
primary SARS-CoV-2 infection elicited at least short-term 
protec tion against reinfection, neutralising antibody titres 
of the magnitude found in our study after boosting 
appeared sufficient to confer protection using the Marburg 
VN assay methodology.19 Neutralising antibody titres were 
increased by a two-dose regimen, and further investi-
gation of this approach is underway. The correlation of 
neutralisation assays with IgG quantitation indicates that, 
if confirmed, a standardised ELISA might be sufficient to 
predict protection, should neutralising antibody also be 
shown to be protective in humans. We have presented data 
from three different live neutralising antibody assays and a 
pseudo-neutralisation assay, which show tight correlation 
with each other but give very different neutralising 
antibody titres. This issue highlights the urgent need for 
centralised laboratory infrastructure to allow bridging 
between vaccine candi dates and accelerate the availability 
of multiple products to provide the global capacity to end 
the pandemic. If any one candidate demonstrates efficacy, 
bridging this result to other candidate vaccines through 
rigorously conducted labo ratory assays will become a 
crucial issue for global health.
Importantly, there are accumulating data to suggest 
T-cell responses play an important role in COVID-19 
mitigation; individuals who were exposed but asymp-
tomatic developed a robust memory T-cell response 
without symptomatic disease in the absence of a 
measurable humoral response.20–22 Adenovirus-vectored 
vaccines are known to induce strong cellular immunity 
and ChAdOx1 nCoV-19 vaccination resulted in marked 
increases in SARS-CoV-2 spike-specific effector T-cell 
responses as early as day 7, peaking at day 14 and 
maintained up to day 56 as expected with adenoviral 
vectors. However, a boost in cellular responses was not 
observed following the second ChAdOx1 nCoV-19 dose. 
This is consistent with previous findings on viral vectored 
vaccines given as part of a homologous prime-boost 
regimen.12
Severe and fatal cases of COVID-19 disproportionally 
affect older individuals. Therefore, it is important that 
vaccines developed to reduce or prevent COVID-19 are 
suitable for administration in older age groups. Immuno-
genicity of a ChAdOx1-vectored vaccine against influenza 
has been shown in older adults (50–78 years of age).6 
As previously reported,10 anti-vector immunity was low 
before vaccination in UK adults aged 18–55 years, with no 
relationship between the presence of antibodies to 
ChAdOx1 and immune response to the vaccine antigen. 
Future studies will address the potential effect of anti-vector 
antibodies on homologous boosting, although in the 
subgroup reported on here, who received two vaccinations 
28 days apart, there was clear evidence of boosting of 
antibody response to SARS-CoV-2 spike protein.
Limitations of this study include the short follow-up 
reported to date, the small number of participants in the 
prime-boost group, and single-blinded design, although 
staff undertaking clinical evaluation and laboratory staff 
all remained blinded. Additionally, the study findings are 
not easily generalisable, as this is a first-in-human study 
of fairly young and healthy volunteers, the majority of 
whom were white. Further studies are required to assess 
the vaccine in various population groups including older 
age groups, those with comorbidities, and in ethnically 
and geographically diverse populations. The participants 
recruited in this study will be followed up for at least 
1 year and further safety, tolerability, and immuno-
genicity (in addition to efficacy) results will be reported 
when data are available.23–25
In conclusion, ChAdOx1 nCoV-19 was safe, tolerated, 
and immunogenic, while reactogenicity was reduced 
with paracetamol. A single dose elicited both humoral 
and cellular responses against SARS-CoV-2, with a 
booster immunisation augmenting neutralising anti-
body titres. The preliminary results of this first-in-human 
clinical trial supported clinical development progression 
into ongoing phase 2 and 3 trials. Older age groups with 
comorbidities, health-care workers, and those with 
higher risk for SARS-CoV-2 exposure are being recruited 
and assessed for efficacy, safety, and immunogenicity of 
ChAdOx1 nCoV-19 given as a single-dose or two-dose 
administration regimen in further trials conducted in 
the UK and overseas. We will also evaluate the vaccine in 
children, once sufficient safety data have been accumu-
lated in adult studies. Phase 3 trials are now underway 
in Brazil, South Africa, and the UK and will evaluate 
vaccine efficacy in diverse populations.
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